Mild overexpression of MeCP2 causes a progressive neurological disorder in mice
- PMID: 15351775
- DOI: 10.1093/hmg/ddh282
Mild overexpression of MeCP2 causes a progressive neurological disorder in mice
Abstract
Mutations in the X-linked methyl-CpG-binding protein 2 (MECP2), encoding a transcriptional repressor, cause Rett syndrome and a variety of related neurodevelopmental disorders. The vast majority of mutations associated with human disease are loss-of-function mutations, but precisely what aspect of MeCP2 function is responsible for these phenotypes remains unknown. We overexpressed wild-type human protein in transgenic mice using a large genomic clone containing the entire human MECP2 locus. Detailed neurobehavioral and electrophysiological studies in transgenic line MeCP2(Tg1), which expresses MeCP2 at approximately 2-fold wild-type levels, demonstrated onset of phenotypes around 10 weeks of age. Surprisingly, these mice displayed enhanced motor and contextual learning and enhanced synaptic plasticity in the hippocampus. After 20 weeks of age, however, these mice developed seizures, became hypoactive and approximately 30% of them died by 1 year of age. These data demonstrate that MeCP2 levels must be tightly regulated in vivo, and that even mild overexpression of this protein is detrimental. Furthermore, these results support the possibility that duplications or gain-of-function mutations in MECP2 might underlie some cases of X-linked delayed-onset neurobehavioral disorders.
Similar articles
-
X-Chromosome inactivation ratios affect wild-type MeCP2 expression within mosaic Rett syndrome and Mecp2-/+ mouse brain.Hum Mol Genet. 2004 Jun 15;13(12):1275-86. doi: 10.1093/hmg/ddh142. Epub 2004 Apr 28. Hum Mol Genet. 2004. PMID: 15115765
-
A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.Nat Genet. 2001 Mar;27(3):322-6. doi: 10.1038/85899. Nat Genet. 2001. PMID: 11242117
-
Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations.Curr Opin Neurol. 2001 Apr;14(2):171-6. doi: 10.1097/00019052-200104000-00006. Curr Opin Neurol. 2001. PMID: 11262731 Review.
-
A WW domain binding region in methyl-CpG-binding protein MeCP2: impact on Rett syndrome.J Mol Med (Berl). 2004 Feb;82(2):135-43. doi: 10.1007/s00109-003-0497-9. Epub 2003 Nov 15. J Mol Med (Berl). 2004. PMID: 14618241
-
MeCP2 in neurons: closing in on the causes of Rett syndrome.Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R19-26. doi: 10.1093/hmg/ddi102. Hum Mol Genet. 2005. PMID: 15809268 Review.
Cited by
-
Partial rescue of Rett syndrome by ω-3 polyunsaturated fatty acids (PUFAs) oil.Genes Nutr. 2012 Jul;7(3):447-58. doi: 10.1007/s12263-012-0285-7. Epub 2012 Mar 8. Genes Nutr. 2012. PMID: 22399313 Free PMC article.
-
Understanding autism spectrum disorders with animal models: applications, insights, and perspectives.Zool Res. 2021 Nov 18;42(6):800-824. doi: 10.24272/j.issn.2095-8137.2021.251. Zool Res. 2021. PMID: 34755500 Free PMC article. Review.
-
Differential methylation of the micro-RNA 7b gene targets postnatal maturation of murine neuronal Mecp2 gene expression.Dev Neurobiol. 2014 Apr;74(4):407-425. doi: 10.1002/dneu.22126. Epub 2013 Dec 9. Dev Neurobiol. 2014. PMID: 24039126 Free PMC article.
-
Disruption of MeCP2-TCF20 complex underlies distinct neurodevelopmental disorders.Proc Natl Acad Sci U S A. 2022 Jan 25;119(4):e2119078119. doi: 10.1073/pnas.2119078119. Proc Natl Acad Sci U S A. 2022. PMID: 35074918 Free PMC article.
-
Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations.PLoS One. 2011;6(6):e20733. doi: 10.1371/journal.pone.0020733. Epub 2011 Jun 13. PLoS One. 2011. PMID: 21695138 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases